Sign In
Buy IBRX
$7.18
-0.0500 (-0.692%)
At Close: Jun 03, 2026
Portnoy Law Firm Announces Class Action on Behalf of ImmunityBio, Inc. Investors
02:22pm, Friday, 27'th Mar 2026
LOS ANGELES, March 27, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises ImmunityBio, Inc., (“Super Micro” or the "Company") (NASDAQ: IBRX) investors of a class action on behalf of investors
New York, New York--(Newsfile Corp. - March 27, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of
$IBRX Lawsuit: ImmunityBio, Inc. Sued for Securities Fraud; Investors Should Contact Block & Leviton to Possibly Recover Losses
12:17pm, Friday, 27'th Mar 2026
A lawsuit has been filed against ImmunityBio. ImmunityBio investors should contact Block & Leviton to possibly recover losses from their $IBRX investment.
ImmunityBio vs. Moderna: Which Biotech Has More Upside Potential?
10:16am, Friday, 27'th Mar 2026
IBRX and MRNA hinge on single-drug success, but pipeline depth, growth plans and risks set them apart in the race for biotech upside.
Scalable Biotech Manufacturing Unlocks a $14B Market
09:15am, Friday, 27'th Mar 2026
/PRNewswire/ -- USANewsGroup.com News Commentary - The global cell therapy manufacturing market is hitting a pivotal inflection point. It's projected to
NEW YORK, March 26, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of ImmunityBio
Investor Notice: Robbins LLP Informs Investors of the ImmunityBio, Inc. Class Action Lawsuit
08:10pm, Thursday, 26'th Mar 2026
SAN DIEGO--(BUSINESS WIRE)---- $IBRX #Biotechnology--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ImmunityBio, Inc. (NA
SAN DIEGO, March 26, 2026 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that the ImmunityBio class action lawsuit seeks to represent purchasers or acquirers of ImmunityBio, Inc. (NASD
EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of ImmunityBio, Inc. Investors – IBRX
06:45pm, Thursday, 26'th Mar 2026
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of ImmunityBio, Inc. (NASDAQ: IBRX
ImmunityBio Lead Bladder Cancer Drug Trial Clears Power Check
10:04am, Thursday, 26'th Mar 2026
ImmunityBio Inc. (NASDAQ: IBRX) shares are down during Thursday's premarket session. Year to date, the stock has jumped over 300%.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRX
10:00am, Thursday, 26'th Mar 2026
NEW YORK, March 26, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ImmunityBio, Inc. ("ImmunityBio" or the "Company") (NASDAQ: IBRX). Such investors are advised
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a vertically integrated, commercial-stage immunotherapy company, today announced that based on the Independent Data Monitoring C
Why Is ImmunityBio (IBRX) Down 35.8% Since Last Earnings Report?
12:31pm, Wednesday, 25'th Mar 2026
ImmunityBio (IBRX) reported earnings 30 days ago. What's next for the stock?
IBRX Stock Slides on FDA Warning Over Misleading Cancer Drug Claims
09:25am, Wednesday, 25'th Mar 2026
ImmunityBio stock sinks 21% after the FDA flags misleading claims on cancer drug Anktiva, citing exaggerated benefits and inadequate risk disclosures.
Rosen Law Firm Encourages ImmunityBio, Inc. Investors to Inquire About Securities Class Action Investigation – IBRX
09:00pm, Tuesday, 24'th Mar 2026
NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of ImmunityBio, Inc. (NASDAQ: IBR
